Subgroup analysis of molecular markers in phase III study of high risk low-grade glioma

Bookmark and Share
Published: 1 Jun 2015
Views: 2058
Dr Brigitta Baumert - Robert Janker Klinic, Bonn, Germany

Dr Baumert talks to ecancertv at ASCO 2015 about the results of her subgroup analysis of molecular markers of a randomised phase III study in patients with a high risk low-grade glioma.

The analysis investigated how primary chemotherapy using temozolomide compares to standard radiotherapy, if it prolongs progression-free and overall survival, and whether prognostic molecular factors could be defined.